Zealand Pharma A/S (Zealand Pharma A/S) Interest Expense : $-2.59 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Zealand Pharma A/S's interest expense for the three months ended in Mar. 2024 was $ -0.70 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.59 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Zealand Pharma A/S's Operating Income for the three months ended in Mar. 2024 was $ -37.30 Mil. Zealand Pharma A/S's Interest Expense for the three months ended in Mar. 2024 was $ -0.70 Mil. Zealand Pharma A/S did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zealand Pharma A/S Interest Expense Historical Data

The historical data trend for Zealand Pharma A/S's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Interest Expense Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.48

-0.47

-0.62

-8.04

-3.64

Zealand Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-1.61	-1.26	-0.51	-0.13	-0.70

Zealand Pharma A/S Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.59 Mil.

Zealand Pharma A/S (OTCPK:ZLDPF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zealand Pharma A/S's Interest Expense for the three months ended in Mar. 2024 was $-0.70 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-37.30 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $54.55 Mil.

Zealand Pharma A/S's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Zealand Pharma A/S did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.